Zomedica Provides NYSE American Listing Update

ANN ARBOR, MI - Zomedica Corp. (NYSE American:ZOM), a company focused on veterinary health diagnostics and therapeutic products for animals, has announced ongoing discussions with NYSE American senior regulatory staff regarding compliance with listing standards. Despite facing compliance issues, Zomedica's shares will continue to be listed on the NYSE American for now.

In response to a formal notice received on September 13, 2023, from the NYSE American about non-compliance with listing standards, Zomedica had until March 12, 2024, to undertake measures such as a reverse stock split for compliance. Unable to secure enough votes for a proposed 80:1 share consolidation, the company now focuses on demonstrating sustained price improvement as a strategy to maintain its listed status.

Larry Heaton, CEO of Zomedica, commented on the company's position, emphasizing ongoing efforts to improve share price and the potential positive impact of Zomedica's recent progress and opportunities on its market standing. He also noted that the NYSE American would continue monitoring the company's share price and other developments with a possible delisting if further share price deterioration occurs.